Αποτελέσματα Αναζήτησης
The Breast Cancer Risk Assessment Tool (BCRAT), also known as The Gail Model, allows health professionals to estimate a woman's risk of developing invasive breast cancer over the next five years and up to age 90 (lifetime risk).
- NCI
This tool cannot accurately calculate risk for women with a...
- Breast Cancer Risk in American Women
Based on current incidence rates, 12.9% of women born in the...
- Breast Cancer—Health Professional Version
The most common type of breast cancer is ductal carcinoma,...
- About the Calculator
Learn how the Gail model-based Breast Cancer Risk Assessment...
- NCI
Learn how the Gail model-based Breast Cancer Risk Assessment Tool calculates an individual's estimated risk of developing invasive breast cancer. Created by scientists at the National Cancer Institute and the NSABP.
The NCI Breast Cancer Risk Assessment Tool (BCRAT) was designed for use in the general US population and its instructions warn that it cannot be accurately used for women carrying BRCA1 or BRCA2 mutations. In fact, BCRAT recommends the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) model for such women.
12 Απρ 2021 · Evaluate the accuracy of the Breast Cancer Risk Assessment Tool (BCRAT), International Breast Cancer Intervention Study risk evaluation tool (IBIS), Polygenic Risk Scores (PRS) and combined scores (BCRAT+PRS and IBIS +PRS) to predict the occurrence of invasive breast cancers at 5 years in a French-Canadian population.
Risk-assessment tools are used in routine clinical practice to identify women at increased risk of breast cancer and to inform counselling about lifestyle changes, genetic testing, screening timing or modality, and eligibility for risk-reducing drugs or surgery.
10 Σεπ 2024 · Our current study objective was to provide definitive assessment of whether the BCRAT model, at a threshold of ≥ 3% 5-year incidence risk, is associated with higher long-term breast cancer mortality in postmenopausal women participating in the Women’s Health Initiative (WHI).
The NCI Breast Cancer Risk Assessment Tool (BCRAT) was designed for use in the general US population and its instructions warn that it cannot be accurately used for women carrying BRCA1 or BRCA2 mutations. In fact, BCRAT recommends the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) model for such women.
